Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AstraZeneca

AstraZeneca PLC (LSE:AZN) said its Tezspire drug, developed in collaboration with Amgen, Inc, has been approved in the US for treatment of severe asthma in patients older than 12 years. Tezspire (tezepelumab-ekko) was approved following a Priority Review by the US Food and Drug Administration (FDA) and based on results from the PATHFINDER clinical trial programme and the pivotal NAVIGATOR Phase III trial, in which Tezspire demonstrated superiority across every primary and key secondary endpoint in patients with severe asthma, AstraZeneca said in a statement.

AstraZeneca and Amgen's Tezspire approved in US for severe asthma

THOUSAND OAKS, Calif., Dec. 17, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Amgen and AstraZeneca's Tezspire™ (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.1   To view the Multimedia News Release, please visit: https://www.multivu.com/players/English/8812852-amgen-fda-approval-tezepelumab-severe-asthma-inflammation/ Tezspire was approved following a Priority Review by the FDA and based on results from the PATHFINDER clinical trial program.

FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN THE U.S. FOR SEVERE ASTHMA

AbbVie

CVS Health

Medical Properties Trust

Royalty Pharma

Should investors consider these healthcare dividend stocks amid the current market volatility?

5 Top Healthcare Dividend Stocks To Watch Today

Bristol-Myers

Conagra Brands

Campbell Soup

Merck

AT&T

Viatris

Verizon

Above-average yields alone aren't enough of a reason to start buying.

Is It Time to Buy the 8 Worst-Performing Dividend Stocks of 2021?

Bank of Montreal

And there could be even more increases in the future.

2 Top Dividend Stocks That Just Hiked Their Payouts by 10% or More

Take a look to see if these dogs of the Dow are worth buying.

Is It Time to Buy the Dow's 3 Worst Performing Stocks This Year?

Axis Capital

Ecolab

EastGroup Properties

Eastman Chemical

Four Corners Property Trust

Graco

Hillenbrand

Mastercard

McCormick

Morningstar

Nucor

Owens Corning

RGC Resources

Raymond James

SL Green Realty

SPDR S&P 500 ETF Trust

Universal Health Realty Income Trust

WEC Energy Group

In this article series, we provide a weekly summary of dividend changes. A summary table provides relevant data and key statistics of dividend increases.

Dividend Increases: November 27-December 3, 2021

VanEck Vectors Biotech ETF

Gilead Sciences

Novartis

Sanofi

We cover dividend stocks often at 24/7, as they provide investors with much better income streams than U.S.

Biotech Has Been Crushed: 5 Stocks to Buy Now That Pay Big Dividends

Amgen Inc. is a biotech company specializing in therapeutics for inflammation, oncology, hematology, bone health, cardiovascular disease, and neuroscience areas. Amgen has 34 pipeline programs in phase 3/4 clinical stage, with a combined drug approved in December 2021 and another pending regulatory submission in Q1'22.

Amgen Deserves To Be An Anchor Stock For Biotech Investors

Raytheon Technologies

The market has rallied this year, but bargain opportunities can be found in different pockets of non-tech sectors.

2 Great Blue Chips To Buy In December

THOUSAND OAKS, Calif., Dec. 6, 2021 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new data from its hematology pipeline and marketed portfolio to be presented at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Georgia, and virtually, from Dec. 11-14, 2021.

Amgen Announces New Data Being Presented At ASH 2021

GlaxoSmithKline

These three pharmaceutical stocks could buffer your portfolio against further market turbulence.

3 Must-Own Dividend Stocks in This Chaotic Market

Amgen carries a number of strong drug franchises and has a burgeoning biosimilar practice. It has a strong track record of capital returns and its dividend yield currently sits well above its historical 10-year range.

Buy Amgen Before Everyone Else Does

NIKE

Dividend growth investors are often fond of saying “a raise is a raise.” For those focused on generating a higher source of income, every dividend increase is appreciated.

2 Companies Handing Out Double-Digit Dividend Increases

Eli Lilly

Pfizer

Roche Holding AG

Roche is optimally diversified both in terms of geography and in terms of portfolio. Pfizer and Eli Lilly are also broadly diversified but are more U.S.-centric companies. AbbVie, but also Merck are currently over-reliant on a single drug but this appears to be priced into the stocks accordingly.

Diversify, Diversify - Concentration Risks Of Several Pharma Companies

American Express

Boeing

Salesforce

Chevron

Disney

Dow Inc

Intel

Coca-Cola

Visa

Walgreens

"The Dow [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration."– Dow Jones & Co. Thirty-one Dow stocks represent nine of eleven sectors. Dow tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated net gains ranged 24.29%-43.88% topped by V 12/1/21.

Dogs Of The Dow Hit December Sporting 2 To Buy

THOUSAND OAKS, Calif., Dec. 3, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.94 per share dividend for the first quarter of 2022.

Amgen Announces 10% Increase In 2022 First Quarter Dividend

Atmos Energy

Darden Restaurants

Morgan Stanley

M&T Bank

Principal Financial Group

Philip Morris

Restaurant Brands

ViacomCBS

Top 10 High Yield Dividend Stocks For December 2021

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?

Amgen (AMGN) Down 7.9% Since Last Earnings Report: Can It Rebound?

Amgen (AMGN) gets FDA nod for the label expansion of Kyprolis in combination with Darzalex Faspro and dexamethasone for treating patients with multiple myeloma at first or subsequent relapse.

Amgen (AMGN) Kyprolis Gets FDA Nod for Use With Darzalex Faspro

News for Amgen Stock (AMGN)